| __timestamp | Exelixis, Inc. | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 50829000 | 59644696 |
| Thursday, January 1, 2015 | 57305000 | 79541000 |
| Friday, January 1, 2016 | 116145000 | 98015000 |
| Sunday, January 1, 2017 | 159362000 | 103958000 |
| Monday, January 1, 2018 | 206366000 | 103654000 |
| Tuesday, January 1, 2019 | 228244000 | 128951000 |
| Wednesday, January 1, 2020 | 293355000 | 135799000 |
| Friday, January 1, 2021 | 401715000 | 149883000 |
| Saturday, January 1, 2022 | 459856000 | 220206000 |
| Sunday, January 1, 2023 | 542705000 | 265542000 |
| Monday, January 1, 2024 | 492128000 |
Infusing magic into the data realm
In the competitive landscape of biotechnology, effective cost management is crucial. Exelixis, Inc. and Travere Therapeutics, Inc. have demonstrated contrasting trends in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Exelixis saw a staggering 967% increase in SG&A expenses, peaking at approximately $543 million in 2023. This growth reflects their aggressive expansion and investment in operational capabilities. In contrast, Travere Therapeutics experienced a more modest 345% rise, reaching around $266 million in the same year. This suggests a more conservative approach, possibly focusing on strategic cost control. These trends highlight the diverse strategies employed by biotech firms in managing operational costs, offering valuable insights for investors and industry analysts alike.
Cost Management Insights: SG&A Expenses for AbbVie Inc. and Exelixis, Inc.
Genmab A/S vs Travere Therapeutics, Inc.: SG&A Expense Trends
Insmed Incorporated or Exelixis, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Apellis Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Bausch Health Companies Inc.
Operational Costs Compared: SG&A Analysis of Exelixis, Inc. and Supernus Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Alpine Immune Sciences, Inc. or Travere Therapeutics, Inc.
Amneal Pharmaceuticals, Inc. vs Travere Therapeutics, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Amicus Therapeutics, Inc. vs Travere Therapeutics, Inc.
Breaking Down SG&A Expenses: ImmunityBio, Inc. vs Travere Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Protagonist Therapeutics, Inc. and Travere Therapeutics, Inc.
Selling, General, and Administrative Costs: Ligand Pharmaceuticals Incorporated vs Travere Therapeutics, Inc.